Email this article 
Hide
Show all
FCA 1 Anaesthetic Refresher Course
Atypical opioids
Southern African Journal of Anaesthesia and Analgesia | Vol 29, No 6 | a1485 |
DOI: https://doi.org/10.36303/SAJAA.3052
| © 2023 S. Mayet
| This work is licensed under Other
Submitted: 30 November 2025 | Published: 30 December 2023
Submitted: 30 November 2025 | Published: 30 December 2023
About the author(s)
S. Mayet, Department of Anaesthesia, School of Clinical Medicine, Faculty of Health Sciences, Rahima Moosa Mother and Child Hospital, University of the Witwatersrand, South AfricaFull Text:
PDF (125KB)Abstract
Opiates and opioids remain the main pillars of analgesia. Their use is, however, limited by abuse potential as well as their side effect profile. Thus, there is a need for the development of newer opioids. The atypical opioids tramadol, tapentadol, dextromethorphan (DXM), and buprenorphine are newer synthetic opioids. These opioids do not solely depend on mu-receptor agonism for their analgesic effects. Except for DXM, atypical opioids are now being used more than conventional opioids as part of chronic pain management.
Keywords
atypical opioids; chronic pain management
Metrics
Total abstract views: 84Total article views: 44